JP Patent

JP7301921B2 — プロタンパク質転換酵素サブチリシン／ケキシン（ｐｃｓｋ９）遺伝子関連障害を治療するための方法および組成物

Assigned to Alnylam Pharmaceuticals Inc · Expires 2023-07-03 · 3y expired

What this patent protects

Patent listed against inclisiran-sodium.

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: JP7301921B2
Jurisdiction: JP
Classification: —
Expires: 2023-07-03
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.